ZIDITUF-TZ 1.125 Injection

ZIDITUF-TZ 1.125 Injection is a powerful combination of Ceftazidime 1000mg and Tazobactam 125mg, formulated to provide broad-spectrum antibacterial coverage against both gram-positive and gram-negative bacteria. It is widely used in hospitals and clinical settings for the treatment of severe infections where other antibiotics may fail.

Key Benefits

• Provides broad-spectrum antibacterial action against resistant bacterial strains

• Combats infections caused by beta-lactamase-producing organisms

• Helps in rapid infection control with fewer relapses

• Reduces hospitalization duration by improving recovery time

• Trusted by healthcare professionals for serious bacterial infections

Indications

ZIDITUF-TZ 1.125 Injection is indicated for:

• Lower respiratory tract infections (including pneumonia and bronchitis)

• Urinary tract infections (UTI)

• Skin and soft tissue infections

• Bone and joint infections

• Intra-abdominal and gynecological infections

• Septicemia and bacterial meningitis (as per physician’s direction)

Mode of Action

• Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis, leading to bacterial death.

• Tazobactam is a beta-lactamase inhibitor that protects ceftazidime from enzymatic degradation, enhancing its effectiveness against resistant bacteria.

Dosage and Administration

• Administered via intravenous (IV) or intramuscular (IM) route as directed by a healthcare professional.

• Dosage depends on the severity of infection, patient age, and clinical condition.

• It is recommended to complete the full prescribed course for best results and to prevent resistance.

Ingredients

• Active Ingredients:

  • Ceftazidime 1000 mg

  • Tazobactam 125 mg

• Excipients: Sterile base suitable for injection.

Storage

• Store below 25°C in a cool, dry place.

• Protect from light and moisture.

• Keep out of reach of children.

Safety Information

• Use only under medical supervision.

• Not recommended for patients with known hypersensitivity to cephalosporins or penicillins.

• Adjust dose in patients with renal impairment.